Sandeep Kapoor, MD
Internal Medicine · Studio City, CANPI 1689860165
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Daiichi Sankyo Inc. at 46.5% of the total. Reporting peaked in 2022 at $1,073 and has fallen 52.6% since, to $508 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$2K
- Collegium Pharmaceutical, Inc.$591
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$579
- Regeneron Healthcare Solutions, Inc.$467
- Merck$262
- AbbVie$243
- plus $694 from 11 others
What the payments were for
- Food & beverage$5,277100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 148 | $2,463 |
| Collegium Pharmaceutical, Inc. | 30 | $591 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $579 |
| Regeneron Healthcare Solutions, Inc. | 6 | $467 |
| Merck | 15 | $262 |
| AbbVie(2 entities) | 11 | $243 |
| Biodelivery Sciences International, Inc. | 2 | $149 |
| Eisai Inc. | 5 | $127 |
| Neurocrine Biosciences, Inc. | 3 | $84 |
| Novo Nordisk | 4 | $73 |
| IBSA Pharma Inc. | 3 | $67 |
| Biofire Diagnostics, LLC | 3 | $56 |
| Arbor Pharmaceuticals, Inc. | 3 | $50 |
| AstraZeneca | 2 | $27 |
| Redhill Biopharma Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Pfizer | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,299 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 43 | $81,896 |
| EliquisApixaban | 96 | $62,827 |
| EntrestoSacubitril/Valsartan | 28 | $19,077 |
| LinzessLinaclotide | 13 | $16,152 |
| XareltoRivaroxaban | 18 | $15,651 |
| Bydureon BciseExenatide Microspheres | 13 | $15,610 |
| Xtampza ErOxycodone Myristate | 14 | $15,482 |
| RybelsusSemaglutide | 15 | $14,548 |
| OzempicSemaglutide | 13 | $12,457 |
| LivaloPitavastatin Calcium | 20 | $11,453 |
| MyrbetriqMirabegron | 18 | $8,507 |
| VascepaIcosapent Ethyl | 17 | $7,731 |
| JanuviaSitagliptin Phosphate | 13 | $7,397 |
| BrilintaTicagrelor | 12 | $5,436 |
| Kombiglyze XrSaxagliptin Hcl/Metformin Hcl | 11 | $3,642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $62,82796 claims |
| Novo NordiskRybelsus, Ozempic | $73 | $27,00528 claims |
| AbbVieLinzess, Synthroid | $243 | $18,58941 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $591 | $15,48214 claims |
| MerckJanuvia | $262 | $7,39713 claims |
| AstraZenecaBrilinta | $27 | $5,43612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Studio City
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.